iX Biopharma has been granted a patent in Israel for its WaferiX drug delivery technology. The patent will expire on October 11, 2033, and will provide key intellectual property protection for the company's WaferiX delivery technology platform in Israel.

The company has also received a patent from the United States Patent and Trademark Office (USPTO), which will expire on October 26, 2030.

iX Biopharma says its intellectual property rights for its sublingual wafer technology is now secured in five continents and all key markets including the US, China, Australia, New Zealand, Singapore, Malaysia, Japan, and South Korea.

To continue reading,

Sign in to access this Premium article.

Subscription entitlements:

Less than $9 per month
3 Simultaneous logins across all devices
Unlimited access to latest and premium articles
Bonus unlimited access to online articles and virtual newspaper on The Edge Malaysia (single login)

Stay updated with Singapore corporate news stories for FREE

Follow our Telegram | Facebook